SEARCH

SEARCH BY CITATION

References

  • 1
    Rampton DS. Methotrexate in Crohn's disease. Gut 2001; 48: 7901.
  • 2
    Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 3536.
  • 3
    Feagan BG, Rochon J, Fedorak RN, et al. (for the North American Crohn's Study Group Investigators). Methotrexate in the treatment of Crohn's disease. N Engl J Med 1995; 332: 2927.
  • 4
    Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomised, Israel multicentre trial. Am J Gastroenterol 1997; 92: 22039.
  • 5
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 16646.
  • 6
    Zenjari T, Lemann M, Mesnard B, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Gastroenterology 1996; 110: A1053(Abstract).
  • 7
    Chong RY, Hanauer SB, Cohen RD. Methotrexate in Crohn's disease: how is it doing? Gastroenterology 1998; 114: A951(Abstract).
  • 8
    Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 17304.
  • 9
    Mahadevan U, Marion JF, Present DH. The place of methotrexate in the treatment of refractory Crohn's disease. Gastroenterology 1997; 112: 10311031.
  • 10
    Vandepunte L, D'Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflammatory Bowel Disease 1999; 5: 115.
  • 11
    Lemann M, Chamiot-Prieur C, Mesnard B, et al. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 1996; 10: 30914.
  • 12
    Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996; 71: 6980.
  • 13
    Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomised, Israeli multicentre trial. Gastroenterology 1996; 110: 141621.
  • 14
    Fraser AG, Orchard T, Jewell D. The safety and efficacy of azathioprine for the treatment of inflammatory bowel disease — a 30-year audit. Gut 2002: in press.
  • 15
    Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumour necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001; 96: 197797.
  • 16
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 17
    Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblatt ME. Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 2103.
  • 18
    Te HS, Schiano TD, Kuan SF, Hanauer SB. Is long-term methotrexate use hepatotoxic in inflammatory bowel disease patients? Gastoenterology 1999; 116: A575A575(Abstract).
  • 19
    Bergquist SR, Felson DT, Prashker MJ, Freeberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthr Rheum 1995; 38: 32633.
  • 20
    Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthr Rheum 1995; 38: 11159.
  • 21
    Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997; 23: 95567.
  • 22
    Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflammatory Bowel Disease 2000; 6: 2517.
  • 23
    Ward MM. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980–1995: results from the National Ambulatory Care Surveys. J Rheumatol 1999; 26: 54650.